BRPI0818762B8 - composição farmacêutica bicamada de liberação imediata e controlada contendo tramadol e acetaminofeno, e, uso de uma composição - Google Patents

composição farmacêutica bicamada de liberação imediata e controlada contendo tramadol e acetaminofeno, e, uso de uma composição

Info

Publication number
BRPI0818762B8
BRPI0818762B8 BRPI0818762A BRPI0818762A BRPI0818762B8 BR PI0818762 B8 BRPI0818762 B8 BR PI0818762B8 BR PI0818762 A BRPI0818762 A BR PI0818762A BR PI0818762 A BRPI0818762 A BR PI0818762A BR PI0818762 B8 BRPI0818762 B8 BR PI0818762B8
Authority
BR
Brazil
Prior art keywords
acetaminophen
composition
controlled release
release pharmaceutical
bilayer
Prior art date
Application number
BRPI0818762A
Other languages
English (en)
Inventor
Bichara Ali
Smith Damon
Le Garrec Dorothée
Ouajdi Patricia
Taga Samir
Gosein Shiva
Gervais Sonia
Sant Vinayak
Lemaire Vincent
Original Assignee
Chimigen Inc
Labopharm Barbados Ltd
Labopharm Europe Ltd
Labopharm Inc
Paladin Labs Barbados Inc
Paladin Labs Europe Ltd
Paladin Labs Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chimigen Inc, Labopharm Barbados Ltd, Labopharm Europe Ltd, Labopharm Inc, Paladin Labs Barbados Inc, Paladin Labs Europe Ltd, Paladin Labs Inc filed Critical Chimigen Inc
Publication of BRPI0818762A2 publication Critical patent/BRPI0818762A2/pt
Publication of BRPI0818762A8 publication Critical patent/BRPI0818762A8/pt
Publication of BRPI0818762B1 publication Critical patent/BRPI0818762B1/pt
Publication of BRPI0818762B8 publication Critical patent/BRPI0818762B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

composição de bicamada para a liberação de tramadol e acetaminofeno, uso de uma composição, e, método de tratar um mamífero em necessidade de analgesia. a invenção diz respeito a uma composição de bicamada para a liberação de acetaminofeno e tramadol em pelo menos um período de doze horas a seguir da administração inicial. uma única administração da composição de bicamada pode fornecer analgesia iniciando em menos do que meia hora depois da administração inicial com uma duração de pelo menos doze horas depois da administração inicial.
BRPI0818762A 2007-10-16 2008-10-15 composição farmacêutica bicamada de liberação imediata e controlada contendo tramadol e acetaminofeno, e, uso de uma composição BRPI0818762B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US98020307P 2007-10-16 2007-10-16
US60/980203 2007-10-16
PCT/CA2008/001799 WO2009049405A1 (en) 2007-10-16 2008-10-15 Bilayer composition for the sustained release of acetaminophen and tramadol

Publications (4)

Publication Number Publication Date
BRPI0818762A2 BRPI0818762A2 (pt) 2015-04-07
BRPI0818762A8 BRPI0818762A8 (pt) 2017-09-19
BRPI0818762B1 BRPI0818762B1 (pt) 2019-07-02
BRPI0818762B8 true BRPI0818762B8 (pt) 2021-05-25

Family

ID=40566952

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0818762A BRPI0818762B8 (pt) 2007-10-16 2008-10-15 composição farmacêutica bicamada de liberação imediata e controlada contendo tramadol e acetaminofeno, e, uso de uma composição

Country Status (15)

Country Link
US (1) US8895066B2 (pt)
EP (1) EP2203166B1 (pt)
JP (1) JP5453280B2 (pt)
KR (1) KR20100069685A (pt)
CN (1) CN101827590A (pt)
AR (1) AR068891A1 (pt)
AU (1) AU2008314454A1 (pt)
BR (1) BRPI0818762B8 (pt)
CA (1) CA2678092C (pt)
CO (1) CO6270218A2 (pt)
ES (1) ES2541809T3 (pt)
MX (1) MX336494B (pt)
RU (1) RU2469718C2 (pt)
TW (1) TW200927196A (pt)
WO (1) WO2009049405A1 (pt)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090162431A1 (en) * 2002-09-21 2009-06-25 Shuyi Zhang Sustained release formulations containing acetaminophen and tramadol
US8377453B2 (en) 2008-03-11 2013-02-19 Depomed, Inc. Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
US8372432B2 (en) 2008-03-11 2013-02-12 Depomed, Inc. Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
US9198861B2 (en) 2009-12-22 2015-12-01 Mallinckrodt Llc Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
US8597681B2 (en) 2009-12-22 2013-12-03 Mallinckrodt Llc Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
AR082167A1 (es) 2010-07-14 2012-11-14 Gruenenthal Gmbh Formas de dosificacion gastrorretentivas
CN102670542A (zh) * 2011-03-17 2012-09-19 北京天衡药物研究院 盐酸曲马多渗透泵控释片
US9050335B1 (en) 2011-05-17 2015-06-09 Mallinckrodt Llc Pharmaceutical compositions for extended release of oxycodone and acetaminophen resulting in a quick onset and prolonged period of analgesia
US8741885B1 (en) 2011-05-17 2014-06-03 Mallinckrodt Llc Gastric retentive extended release pharmaceutical compositions
US8858963B1 (en) 2011-05-17 2014-10-14 Mallinckrodt Llc Tamper resistant composition comprising hydrocodone and acetaminophen for rapid onset and extended duration of analgesia
US10702485B2 (en) 2011-07-09 2020-07-07 Syntrix Biosystems Inc. Compositions and methods for overcoming resistance to tramadol
ES2681952T3 (es) * 2013-03-15 2018-09-17 SpecGx LLC Forma farmacéutica sólida disuasoria del abuso de liberación inmediata con puntaje funcional
DE102013009114A1 (de) 2013-05-29 2014-12-04 Franz Gerstheimer Pharmazeutische Zusammensetzung zur Überwindung von Metabolisierungsproblemen
KR101710792B1 (ko) * 2015-07-14 2017-02-28 주식회사 유영제약 세레콕시브 및 트라마돌을 함유하는 약제학적 조성물
US9693949B1 (en) * 2015-12-22 2017-07-04 Revogenex Ireland Ltd Intravenous administration of tramadol
US9980900B2 (en) * 2015-12-22 2018-05-29 Revogenex Ireland Ltd Intravenous administration of tramadol
ES2913642T3 (es) * 2017-10-13 2022-06-03 Altus Formulation Inc Excipientes modificadores de la liberación a base de almidón y composiciones farmacéuticas derivadas de los mismos
GB2567493B (en) 2017-10-13 2019-12-18 Altus Formulation Inc Starch-based release modifying excipients and pharmaceutical compositions derived therefrom
US11000488B2 (en) 2019-03-22 2021-05-11 Syntrix Biosystems Inc. Treating pain using desmetramadol
DE102021210130A1 (de) * 2021-09-14 2023-03-16 Robert Bosch Gesellschaft mit beschränkter Haftung Fluidleitvorrichtung für einen Scheibenwischer
KR20240105295A (ko) * 2022-12-28 2024-07-05 주식회사 삼양홀딩스 룩소리티닙의 다중 방출제어 정제 조성물 및 이의 제조 방법

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3652589A (en) * 1967-07-27 1972-03-28 Gruenenthal Chemie 1-(m-substituted phenyl)-2-aminomethyl cyclohexanols
US4968509A (en) * 1987-07-27 1990-11-06 Mcneilab, Inc. Oral sustained release acetaminophen formulation and process
US5004613A (en) * 1987-07-27 1991-04-02 Mcneil-Ppc, Inc. Oral sustained release pharmaceutical formulation and process
US4820522A (en) * 1987-07-27 1989-04-11 Mcneilab, Inc. Oral sustained release acetaminophen formulation and process
US5133974A (en) * 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
US5603956A (en) * 1990-11-27 1997-02-18 Labopharm Inc. Cross-linked enzymatically controlled drug release
CA2041774C (en) * 1990-11-27 1994-04-19 Mircea A. Mateescu Use of cross-linked amylose as a matrix for the slow release of biologically active compounds
CA2095523C (en) 1991-09-06 2004-06-22 Robert B. Raffa Composition comprising a tramadol material and acetaminophen and its use
US5478577A (en) * 1993-11-23 1995-12-26 Euroceltique, S.A. Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
US5616343A (en) * 1993-03-25 1997-04-01 Labopharm, Inc. Cross-linked amylose as a binder/disintegrant in tablets
NZ260408A (en) * 1993-05-10 1996-05-28 Euro Celtique Sa Controlled release preparation comprising tramadol
IL110014A (en) * 1993-07-01 1999-11-30 Euro Celtique Sa Solid controlled-release oral dosage forms of opioid analgesics
IT1264696B1 (it) * 1993-07-09 1996-10-04 Applied Pharma Res Forme farmaceutiche destinate alla somministrazione orale in grado di rilasciare sostanze attive a velocita' controllata e differenziata
DE4329794C2 (de) * 1993-09-03 1997-09-18 Gruenenthal Gmbh Tramadolsalz enthaltende Arzneimittel mit verzögerter Wirkstofffreisetzung
US6210714B1 (en) * 1993-11-23 2001-04-03 Euro-Celtique S.A. Immediate release tablet cores of acetaminophen having sustained-release coating
GB9519363D0 (en) * 1995-09-22 1995-11-22 Euro Celtique Sa Pharmaceutical formulation
AUPN605795A0 (en) * 1995-10-19 1995-11-09 F.H. Faulding & Co. Limited Analgesic pharmaceutical composition
US5773031A (en) * 1996-02-27 1998-06-30 L. Perrigo Company Acetaminophen sustained-release formulation
US5807575A (en) * 1997-02-14 1998-09-15 Rougier Inc. Manufacture of cross-linked amylose useful as a excipient for control release of active compounds
BE1011045A3 (fr) * 1997-03-14 1999-04-06 Ucb Sa Compositions pharmaceutiques pour la liberation controlee de substances actives.
FR2772615B1 (fr) * 1997-12-23 2002-06-14 Lipha Comprime multicouche pour la liberation instantanee puis prolongee de substances actives
US6284273B1 (en) * 1998-02-24 2001-09-04 Vincent Lenaerts Cross-linked high amylose starch resistant to amylase as a matrix for the slow release of biologically active compounds
US6245357B1 (en) * 1998-03-06 2001-06-12 Alza Corporation Extended release dosage form
US6156342A (en) * 1998-05-26 2000-12-05 Andex Pharmaceuticals, Inc. Controlled release oral dosage form
IT1301966B1 (it) * 1998-07-30 2000-07-20 Zambon Spa Composizioni farmaceutiche ad attivita' analgesica
US6245387B1 (en) * 1998-11-03 2001-06-12 Diamon-Fusion International, Inc. Capped silicone film and method of manufacture thereof
ES2255490T3 (es) * 1999-03-31 2006-07-01 Janssen Pharmaceutica N.V. Almidon pregelatinizado en una formulacion de liberacion controlada.
WO2001045676A2 (en) 1999-12-20 2001-06-28 Schering Corporation Extended release oral dosage composition
US6761895B2 (en) * 2000-04-17 2004-07-13 Yamanouchi Pharmaceutical Co., Ltd. Drug delivery system for averting pharmacokinetic drug interaction and method thereof
GB0009522D0 (en) * 2000-04-19 2000-06-07 Smithkline Beecham Plc Composition
US6955821B2 (en) * 2000-04-28 2005-10-18 Adams Laboratories, Inc. Sustained release formulations of guaifenesin and additional drug ingredients
US6607748B1 (en) * 2000-06-29 2003-08-19 Vincent Lenaerts Cross-linked high amylose starch for use in controlled-release pharmaceutical formulations and processes for its manufacture
BR0114395A (pt) * 2000-10-03 2005-08-16 Penwest Pharmaceuticals Compan Composição farmacêutica para administração por suprimento via oral
US20020106408A1 (en) * 2000-12-01 2002-08-08 Johnatan Bacon Prolamin-based sustained-release compositions and delayed-onset compositions
US6968551B2 (en) * 2001-06-11 2005-11-22 John Hediger System and user interface for generation and processing of software application installation instructions
US20030092724A1 (en) * 2001-09-18 2003-05-15 Huaihung Kao Combination sustained release-immediate release oral dosage forms with an opioid analgesic and a non-opioid analgesic
US8329217B2 (en) * 2001-11-06 2012-12-11 Osmotica Kereskedelmi Es Szolgaltato Kft Dual controlled release dosage form
KR100522239B1 (ko) 2002-07-16 2005-10-18 주식회사 서울제약 아세트아미노펜을 함유하는 제어방출성의 경구용 제제
AU2003271024A1 (en) * 2002-09-21 2004-04-08 Jin Wang Sustained release compound of acetamidophenol and tramadol
TWI319713B (en) * 2002-10-25 2010-01-21 Sustained-release tramadol formulations with 24-hour efficacy
US8487002B2 (en) * 2002-10-25 2013-07-16 Paladin Labs Inc. Controlled-release compositions
MXPA05004410A (es) * 2002-10-25 2005-11-23 Labopharm Inc Composiciones de liberacion controlada.
CA2419349A1 (en) * 2003-02-20 2004-08-20 Geoffrey Lambert A modular display holder for a card
US20080031901A1 (en) * 2004-09-24 2008-02-07 Abbott Laboratories Sustained release monoeximic formulations of opioid and nonopioid analgesics
KR20060092255A (ko) * 2003-09-26 2006-08-22 알자 코포레이션 고도의 약물적재를 제공하는 약물코팅제 및 그의 제조방법
US20060172006A1 (en) * 2003-10-10 2006-08-03 Vincent Lenaerts Sustained-release tramadol formulations with 24-hour clinical efficacy
CN1926728A (zh) * 2004-01-07 2007-03-07 光谱物理学公司 工业用直接二极管泵浦超快速放大器系统
US7622137B2 (en) * 2004-05-21 2009-11-24 Accu-Break Technologies, Inc. Dosage forms contained within a capsule or sachet
US8541026B2 (en) * 2004-09-24 2013-09-24 Abbvie Inc. Sustained release formulations of opioid and nonopioid analgesics
US20060257473A1 (en) * 2005-05-11 2006-11-16 Porranee Puranajoti Extended release tablet
HUE053838T2 (hu) * 2005-08-24 2021-07-28 Endo Pharmaceuticals Inc Nyújtott felszabadulású nabulfin-készítmények
DK1940467T3 (da) * 2005-09-09 2017-02-13 Paladin Labs Inc Lægemiddelsammensætning med langvarig frigivelse
EP1993518A4 (en) * 2006-03-06 2012-12-12 Pozen Inc DOSAGE FORMS FOR THE ADMINISTRATION OF MEDICINAL COMBINATIONS
US20070237816A1 (en) * 2006-04-06 2007-10-11 David Finkelstein Acetaminophen formulation for joint pain relief

Also Published As

Publication number Publication date
RU2469718C2 (ru) 2012-12-20
EP2203166A1 (en) 2010-07-07
AR068891A1 (es) 2009-12-16
CO6270218A2 (es) 2011-04-20
CN101827590A (zh) 2010-09-08
EP2203166A4 (en) 2012-07-04
TW200927196A (en) 2009-07-01
BRPI0818762A8 (pt) 2017-09-19
RU2010119463A (ru) 2011-11-27
JP5453280B2 (ja) 2014-03-26
US8895066B2 (en) 2014-11-25
CA2678092A1 (en) 2009-04-23
BRPI0818762B1 (pt) 2019-07-02
WO2009049405A1 (en) 2009-04-23
ES2541809T3 (es) 2015-07-24
BRPI0818762A2 (pt) 2015-04-07
MX336494B (es) 2016-01-21
EP2203166B1 (en) 2015-05-06
US20090130183A1 (en) 2009-05-21
AU2008314454A1 (en) 2009-04-23
CA2678092C (en) 2013-07-30
MX2010004236A (es) 2010-09-07
KR20100069685A (ko) 2010-06-24
JP2011500607A (ja) 2011-01-06

Similar Documents

Publication Publication Date Title
BRPI0818762B8 (pt) composição farmacêutica bicamada de liberação imediata e controlada contendo tramadol e acetaminofeno, e, uso de uma composição
CL2011000501A1 (es) Composición farmacéutica que comprende un agonista de gpr119 en combinación con un inhibidor de dpp-4 seleccionado de un grupo definido; uso para prevenir y/o tratar enfermedades metabólicas, como resistencia insulinica, diabetes, sindrome metabolico, obesidad, hiperlipidemia, osteoporosis, entre otras.
EA200802184A1 (ru) Фармацевтические композиции с ингибиторами dpp iv
CL2010001526A1 (es) Compuestos derivados de isonicotinamida, moduladores de la estearoil-coa-desaturasa; composicion farmaceutica que comprende un compuesto;utiles para tratar enfermedades relacionadas con dislipidemia y trastornos del metabolismo de lipidos.
BRPI0609393B8 (pt) usos de um composto 11-desóxi-prostaglandina
BR112012011128A2 (pt) composição farmacêutica compreendendo um agonista de glp-1, uma insulina e uma metionina
UY30304A1 (es) Moduladores de mglur5 i
AR061967A1 (es) Ester isopropilico del acido 4-[6-(6-metanosulfonil-2-metil-piridin-3-il-amino)-5-metil-pirimidin-4-iloxi]-piperidin-i-carboxilico, composicion farmaceutica que lo comprende y un metodo de preparacion de la misma y el uso de este compuesto para el tratamiento de trastornos metabolicos
ECSP10010684A (es) Agonistas mezclados, basados en gip para el tratamiento de trastornos metabólicos y obesidad.
CL2008002424A1 (es) Composicion farmaceutica que comprende un compuesto derivado de pirazol-o-glucosido; y uso de la composicion farmaceutica para el tratamiento de la diabetes mellitus, tolerancia anormal a la glucosa e hiperglucemia, trastornos metabolicos, entre otras.
BRPI0607762B8 (pt) análogos de glp-1, composição farmacêutica contendo os mesmos e uso de um composto
BR112012011403B8 (pt) composição farmacêutica líquida compreendendo um agonista glp-1 e metionina e uso da mesma
CL2007001915A1 (es) Compuesto cristalino de 6-[4-cloro-3-(4-etoxibencil)fenil]tetrahidropiran-2,3,4,5,-tetraol; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y su uso para preparar un medicamento para tratar diabetes, dislipidemia, obesidad, entre otras.
BRPI0706676B8 (pt) uso de uma solução aquosa com potencial de oxirredução
EA201101187A1 (ru) Антидиабетические лекарственные средства, содержащие ингибитор dpp-4 (линаглиптин) необязательно в комбинации с другими антидиабетическими средствами
BRPI0909625A2 (pt) agonista seletivo do receptor s1p1 para o uso como um medicamento, uso do mesmo e kit que contém diferentes unidades de medicação de um agonista seletivo do receptor s1p1
ECSP099612A (es) Derivados de bencimidazol y sus métodos de uso
CL2008001671A1 (es) Compuestos derivados de piperidina/piperazina inhibidores de dgat1, composicion farmaceutica que los comprende; y su uso en el tratamiento de enfermedades metabolicas especialmente diabetes.
CL2009000309A1 (es) Derivados fluoroglicosidos aromaticos, composicion farmaceutica que contenga estos compuestos, procedimiento para prepararla y su uso en el tratamiento de la diabetes tipo 1 y 2.
UY30308A1 (es) Moduladores de mglur5 v
CL2008002247A1 (es) Compuestos derivados de fenil amida; proceso de preparacion; composicion farmaceutica que los contiene; y su uso en la preparacion de medicamentos para el tratamiento de trastornos del sueno, narcolepsia y trastornos psiquiatricos, entre otros.
UY30307A1 (es) Moduladores de mglur5 vi
UY30305A1 (es) Moduladores de mglur5 iv
CL2009001841A1 (es) Uso de una composición de liberación sostenida de 4-aminopiridina para preparar un medicamento útil para tratar esclerosis multiple en un sujeto.
UY30309A1 (es) Moduladores de mglur5 ii

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: LABOPHARM EUROPE LIMITED (IE) , LABOPHARM (BARBADO

B25D Requested change of name of applicant approved

Owner name: LABOPHARM EUROPE LIMITED (IE) , LABOPHARM (BARBADOS) LIMITED (BB) , LABOPHARM INC. (CA)

Owner name: LABOPHARM EUROPE LIMITED (IE) , LABOPHARM (BARBADO

B25A Requested transfer of rights approved

Owner name: LABOPHARM EUROPE LIMITED (IE) , LABOPHARM (BARBADO

B25D Requested change of name of applicant approved

Owner name: LABOPHARM (BARBADOS) LIMITED (BB) , PALADIN LABS I

B25G Requested change of headquarter approved

Owner name: PALADIN LABS INC. (CA) , PALADIN LABS EUROPE LIMIT

B25A Requested transfer of rights approved

Owner name: PALADIN LABS INC. (CA) , PALADIN LABS EUROPE LIMIT

B25D Requested change of name of applicant approved

Owner name: PALADIN LABS INC. (CA) , PALADIN LABS EUROPE LIMIT

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 02/07/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 02/07/2019, OBSERVADAS AS CONDICOES LEGAIS

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 15/10/2008 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B15V Prolongation of time limit allowed